Australian eyecare company Regenera has bought new technology that will expand its treatment options for back-of-the-eye diseases.
The company has bought technology that involves three additional applications for Triamcinolone Acetonide that complements its core Visagen product.
Visagen is under development for the treatment of age-related Macular Degeneration and diabetes-related eye diseases.
Regenera CEO William Ardrey said there were several benefits to the newly acquired technology.
"Firstly it expands the coverage of Visagen from diseases of the back of the eye to include the middle of the eye as well," Dr Ardrey said.
"Secondly it expands coverage to use in surgical procedures and finally, it will also allow Regenera to offer combinatory drug and test kits within the ophthalmic market."